The startup develops a secretoneurin-based biomarker test for diagnosing cardiovascular diseases, specifically targeting life-threatening arrhythmias. This test provides prognostic insights and risk stratification for patients, facilitating the selection of candidates for implantable cardioverter-defibrillator treatment through blood measurement of secretoneurin.
Funding
$2.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Current methods for assessing cardiovascular risk and diagnosing life-threatening arrhythmias often lack the accuracy needed for effective patient stratification. Existing biomarkers may not fully capture the complex pathophysiological pathways, particularly those related to cardiomyocyte calcium handling and arrhythmogenesis. This can lead to both under- and over-treatment of patients at risk of sudden cardiac death.
Solution
CardiNor offers a Secretoneurin (SN) ELISA assay designed to improve risk stratification and provide prognostic insights for patients with or at risk of cardiovascular diseases, including life-threatening arrhythmias and heart failure. The assay measures secretoneurin levels in blood samples, providing clinicians with additional information to aid in the selection of candidates for implantable cardioverter-defibrillator (ICD) treatment and other cardiovascular interventions. Secretoneurin, a neuropeptide associated with cardiomyocyte calcium regulation, serves as an independent predictor of mortality and provides complementary information to existing cardiac biomarkers like troponins and BNP. The CE-IVD registered ELISA kit includes calibrators and controls to ensure accurate and reliable measurements.
Target Audience
The primary target audience includes cardiologists, electrophysiologists, and clinical laboratories involved in cardiovascular risk assessment, heart failure management, and arrhythmia diagnosis.
Features
- ELISA-based assay utilizing two secretoneurin-specific monoclonal antibodies
- Quantitative measurement of secretoneurin levels in blood samples
- Includes calibrators and controls for quality assurance
- Limit of Quantification (LoQ): 7.6 pmol/L
- Limit of Detection (LoD): 5.1 pmol/L
- Linearity: 11.8
- 299.2 pmol/L
- Demonstrated prognostic value in patients with heart failure, acute respiratory failure, and severe sepsis
- Provides independent prognostic information to established risk indices and biomarkers